England is rolling out a gonorrhea vaccination program using the serogroup B meningococcal vaccine (4CMenB), which offers partial cross-protection against Neisseria gonorrhoeae. The program targets high-risk populations and comes amid rising antimicrobial resistance and increasing gonorrhea diagnoses.
According to new research in Therapeutic Advances in Reproductive Health, effective scale-up depends on building trust among young migrants-a group facing structural barriers like language, precarious housing, fear of immigration surveillance, and stigma. Without culturally responsive outreach, the program risks widening sexual health disparities.
Key factors for uptake include privacy, confidentiality, and accessible delivery settings. Researchers recommend multilingual materials, peer support, and community health champions. Acceptability studies should combine focus groups and surveys to understand how young migrants weigh dose number, protection levels, side effects, and wait times.